Company Description
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.
The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.
Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jun 25, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Jill Milne |
Contact Details
Address: 22 Boston Wharf Road, 10th floor Boston, Massachusetts 02210 United States | |
| Phone | 617 349 1971 |
| Website | astriatx.com |
Stock Details
| Ticker Symbol | ATXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001454789 |
| CUSIP Number | 04635X102 |
| ISIN Number | US04635X1028 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jill C. Milne Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Benjamin S. Harshbarger J.D. | Chief Legal Officer |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer |
| Noah C. Clauser CPA | Chief Financial Officer and Treasurer |
| Keri McGrail | Chief Human Resources Officer |
| Andrea L. Matthews | Chief Business Officer |
| Andrew A. Komjathy | Chief Commercial Officer |
| John Ruesch | Senior Vice President of Pharmaceutical Sciences and Technical Operations |
| Rafif Dagher | Senior Vice President and Head of Discovery, Nonclinical Development and Translational Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2025 | SCHEDULE 13G | Filing |
| Jun 12, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |